Introduction to Clovis Oncology Inc.

Clovis Oncology Inc. is a dynamic and innovative biopharmaceutical company headquartered in Boulder, Colorado, with additional operations in the United Kingdom and Switzerland. The company focuses on the discovery, development, and commercialization of targeted anticancer treatments. With a portfolio that includes Rubraca (rucaparib), a PARP inhibitor approved for certain ovarian and prostate cancers, Clovis Oncology has established itself as a key player in the precision oncology space. The company’s mission is to bring meaningful therapies to patients with unmet medical needs, leveraging cutting-edge science and strategic partnerships. Recognized for its commitment to research and clinical excellence, Clovis Oncology collaborates with leading academic institutions and healthcare organizations worldwide. The company’s market reputation is built on a foundation of rigorous clinical trials, patient-centric approaches, and a dedicated workforce of over 500 employees. As a top Healthcare company, Clovis Oncology continues to push boundaries in cancer treatment, earning trust from oncologists, patients, and investors alike. This profile delves into the company’s history, values, operations, and why it remains a premier employer in the biotech sector.

Company History and Business Evolution

Clovis Oncology was founded in 2009 by a team of experienced pharmaceutical executives led by Patrick J. Mahaffy, who served as CEO until his passing in 2024. The company’s name was inspired by Clovis, the first known culture in the Americas, symbolizing discovery and innovation. From its inception, Clovis focused on developing targeted therapies for genetically defined cancers. In 2012, the company acquired the rights to rucaparib from Pfizer, marking a pivotal moment. The drug received accelerated approval from the FDA in 2016 for BRCA-mutated advanced ovarian cancer, followed by approvals for maintenance treatment and later for metastatic castration-resistant prostate cancer. Over the years, Clovis expanded its pipeline through internal research and collaborations, including partnerships with Foundation Medicine and Merck KGaA. The company faced challenges, including patent disputes and commercial competition, but remained resilient by streamlining operations and focusing on its core assets. In 2023, Clovis underwent a restructuring to strengthen its financial position, emerging as a leaner organization with continued commitment to R&D. The evolution of Clovis Oncology reflects the broader trends in precision medicine, where biomarker-driven therapies are transforming oncology care. Key milestones include the launch of Rubraca in multiple markets, expansion into Europe, and ongoing clinical trials exploring combination therapies. Despite market volatility, Clovis has maintained a strong scientific foundation, contributing to the understanding of PARP inhibition. The company’s history is a testament to perseverance and innovation in the face of regulatory and economic hurdles.

Clovis Oncology Inc. at a Glance

• Headquarters: Boulder, Colorado, USA
• Founded: 2009
• CEO: James (Jim) Miller (interim as of 2024)
• Revenue: Approximately $150 million (2023)
• Employees: ~500
• Industry: Biotechnology – Oncology
• Key Product: Rubraca (rucaparib) – PARP inhibitor
• Approved Indications: Ovarian cancer, prostate cancer
• Global Presence: USA, UK, Switzerland
• Stock Symbol: CLVS (formerly on NASDAQ; delisted in 2023)
• Clinical Pipeline: Combination therapies, next-gen PARP inhibitors
• FDA Approvals: 2016, 2018, 2020
• Key Collaborations: Foundation Medicine, Merck KGaA
• Core Technology: Precision medicine, biomarker-driven clinical trials
• Patient Reach: Thousands globally
• Research Focus: DNA damage repair, BRCA mutations
• Corporate Status: Private (after restructuring in 2023)
• Number of Trials: Over 20 active clinical studies
• Awards: Multiple industry recognitions for innovation
• Company Culture: Collaborative, patient-centric, data-driven

Mission, Vision, and Core Corporate Values

Clovis Oncology Inc.'s mission is to develop and deliver transformative therapies that improve the lives of cancer patients through precision medicine. The vision is to become a leading oncology company known for its scientific rigor and patient-first approach. Core values include integrity in research, urgency in bringing treatments to market, respect for all stakeholders, collaboration with the medical community, and accountability for outcomes. The company emphasizes a culture of innovation where every employee contributes to breakthroughs. These values guide daily operations, from clinical trial design to regulatory submissions. Clovis believes that understanding the genetic basis of cancer is key to effective treatments, and thus invests heavily in biomarker research. The commitment to patients extends beyond drug development, encompassing access programs and educational initiatives. The company’s value system also stresses transparency in communication, both internally and with external partners. By adhering to these principles, Clovis Oncology has built a reputation for reliability and excellence in the biotech industry.

Business Strategy and Future Roadmap

Clovis Oncology's business strategy centers on maximizing the potential of its lead asset, Rubraca, while advancing a pipeline of new candidates. Post-restructuring, the company has adopted a leaner operational model to extend cash runway and focus resources on high-value programs. Key strategic pillars include: expanding Rubraca’s label through additional indications and combination therapies; pursuing strategic partnerships to co-develop and commercialize assets; leveraging real-world evidence to support reimbursement and clinical adoption; investing in next-generation DNA damage repair inhibitors; and maintaining a strong intellectual property portfolio. The future roadmap includes completing several Phase I/II combination trials, exploring oral formulations, and potentially entering new geographic markets. Clovis is also exploring digital health solutions to enhance patient monitoring in clinical trials. The company aims to achieve profitability through disciplined spending and revenue growth from Rubraca, while preparing for potential approval of new indications. The roadmap reflects a cautious optimism, balancing scientific ambition with financial prudence. Clovis remains agile, ready to adapt to market changes and scientific advancements. The leadership team emphasizes a return to growth after recent challenges, with a clear focus on delivering value to patients and shareholders.

Products, Technologies, and Services

Clovis Oncology’s primary product is Rubraca (rucaparib), a PARP inhibitor that targets cancers with BRCA mutations or other DNA repair deficiencies. Available in tablet form, Rubraca is indicated for maintenance treatment of recurrent ovarian cancer, advanced ovarian cancer after two or more chemotherapies, and metastatic castration-resistant prostate cancer with BRCA mutations. The technology behind Rubraca involves inhibition of poly (ADP-ribose) polymerase enzymes, leading to synthetic lethality in cancer cells with defective homologous recombination repair. Clovis also offers companion diagnostic services through partnerships with labs to identify eligible patients. Additionally, the company is developing next-generation PARP inhibitors with improved pharmacokinetics and selectivity. Services include patient support programs, educational resources for healthcare providers, and clinical trial access for eligible patients. Clovis collaborates with genomic testing companies to ensure broad access to biomarker testing. The company’s technological edge lies in its deep understanding of DNA damage response pathways and its ability to design trials that rapidly demonstrate clinical benefit. Ongoing R&D explores combinations with immunotherapies and other targeted agents. Clovis also invests in artificial intelligence to analyze clinical data and accelerate drug development. Beyond products, the company provides scientific leadership through publications and conferences, contributing to the oncology community.

Industries and Markets Served

Clovis Oncology primarily serves the healthcare industry, specifically oncology. Its market includes hospitals, cancer centers, community clinics, and academic medical institutions that treat ovarian and prostate cancer patients. The company also engages with diagnostic laboratories, insurance payers, and government health agencies. Geographically, Clovis has a strong presence in the United States, with growing markets in Europe (UK, Switzerland) and select territories through partners. The company addresses the unmet need for targeted therapies in biomarker-selected populations, which is a growing segment of precision oncology. Clovis serves both the initial treatment and maintenance therapy markets, providing ongoing revenue streams. Additionally, the company participates in the clinical research market by conducting investigator-initiated trials and collaborations. The market for PARP inhibitors is competitive, with players like AstraZeneca and GlaxoSmithKline, but Clovis differentiates through its focus on BRCA mutations and unique combination data. The company also serves the healthcare ecosystem by educating pathologists and oncologists about genomic testing. As the industry shifts toward personalized medicine, Clovis is well-positioned to capitalize on the expansion of biomarker-driven therapies. The company’s services extend to patient advocacy groups, ensuring that patient voices are heard in drug development.

Leadership and Management Philosophy

Clovis Oncology's leadership team combines decades of experience in drug development, commercialization, and corporate strategy. The board and executive team emphasize a philosophy of “science first, patients always.” The interim CEO, James Miller, brings expertise in corporate restructuring and operational efficiency. The management style is collaborative, with an open-door policy that encourages cross-functional innovation. Leaders at Clovis are hands-on, often engaging directly with research teams and clinical investigators. The company fosters a culture of mentorship and continuous learning, recognizing that talent development is key to long-term success. Decision-making is data-driven, with regular reviews of clinical and commercial metrics. The leadership also prioritizes ethical conduct and compliance, given the highly regulated environment. Clovis values diversity of thought and background, believing it leads to better problem-solving. The management philosophy is resilient: learning from setbacks, celebrating successes, and adapting quickly to new information. This approach has helped the company navigate financial challenges and maintain focus on its mission. Leaders are also active in industry forums, contributing to policy discussions on cancer care and drug pricing.

Corporate Events, Conferences, and Community Engagement

Clovis Oncology regularly participates in major oncology conferences such as ASCO, ESMO, SGO, and AACR, where it presents clinical trial data and engages with the scientific community. The company also hosts investor days and key opinion leader meetings to discuss pipeline progress. Community engagement includes supporting patient advocacy groups like the Ovarian Cancer Research Alliance and the Prostate Cancer Foundation. Clovis sponsors educational events for healthcare providers and contributes to local science fairs and STEM initiatives in Boulder. The company organizes internal summits to align employees around strategic goals. Additionally, Clovis holds patient-focused roundtables to gather insights on treatment experiences. The company’s philanthropic efforts include donating a portion of revenue to cancer research charities. Clovis also partners with medical schools to provide training on genomic medicine. By maintaining a visible presence in the oncology community, the company builds trust and influences treatment guidelines. The corporate events calendar is a key component of its marketing and relationship-building efforts.

Employees and Workplace Culture

Clovis Oncology offers a dynamic, inclusive workplace that values scientific curiosity and teamwork. Employees enjoy a competitive compensation package, including stock options, health benefits, and flexible work arrangements. The culture is characterized by a shared sense of purpose: to make a difference in patients’ lives. Internal communication is transparent, with regular town halls and updates from leadership. The company invests in professional development through tuition reimbursement and conference attendance. Diversity and inclusion are core tenets, with employee resource groups that foster belonging. The Boulder headquarters provides a vibrant environment with modern lab spaces and collaborative areas. Remote work options are available for certain roles. Employee feedback is actively sought through surveys and pulse checks, leading to continuous improvement. The company recognizes achievements through awards and public acknowledgment. Clovis also promotes work-life balance with generous paid time off and holiday schedules. The atmosphere is high-energy but supportive, with a focus on results rather than hours. Many employees cite the meaningful nature of the work and the camaraderie as reasons for staying. Clovis has been recognized as a “Best Place to Work” in local rankings, reflecting its commitment to employee satisfaction.

Job Details & Requirements for this Posting

Senior Clinical Research Associate (Oncology)

Location: Boulder, Colorado (or remote with travel)

Job Type: Full-time

Salary Range: $90,000 - $120,000 per year (commensurate with experience)

Role Overview: We are seeking an experienced Senior Clinical Research Associate (CRA) to manage and monitor oncology clinical trials. The ideal candidate will ensure compliance with protocols, GCP, and regulatory requirements while supporting sites and patients. This role is integral to the successful execution of our clinical development programs.

Key Responsibilities:

• Conduct site qualification, initiation, monitoring, and close-out visits for Phase I-III oncology studies.
• Verify informed consent processes and ensure patient safety.
• Review clinical data for accuracy and completeness.
• Train site staff on protocol requirements and data entry.
• Identify and escalate issues to clinical project managers.
• Maintain study documentation according to ICH guidelines.
• Collaborate with cross-functional teams (regulatory, data management, medical).
• Contribute to study reports and regulatory submissions.

Qualifications:

• Bachelor’s degree in life sciences or nursing (Master’s preferred).
• Minimum 5 years of clinical monitoring experience, with at least 2 years in oncology.
• Strong knowledge of GCP, FDA regulations, and ICH guidelines.
• Excellent organizational and communication skills.
• Ability to travel up to 40% of the time.
• CRA certification (ACRP or SOCRA) highly desirable.
• Experience with PARP inhibitors or DNA repair agents considered a plus.

Why Join Clovis Oncology? You will be part of a mission-driven team that is changing cancer care. Clovis offers a supportive environment where your contributions directly impact patients. Comprehensive benefits include medical, dental, vision, 401(k) matching, and paid parental leave. This is an opportunity to grow your career in a company with a strong scientific legacy and a promising future.

Customer Reviews and Industry Reputation

Clovis Oncology has a mixed but overall respectful reputation in the industry. Customers (physicians, patients, partners) appreciate the company’s focus on precision medicine and the efficacy of Rubraca in biomarker-selected populations. However, like many biotech firms, it faces challenges in commercialization and competition. Below is a detailed breakdown of reviews from various platforms.

GLASS DOOR

On Glassdoor, Clovis Oncology holds a 3.8 out of 5 rating based on employee reviews. Positive comments highlight the collaborative culture, sense of purpose, and strong science. Employees often mention that the work is meaningful and that they are proud to be part of a company fighting cancer. Negative reviews cite management instability after the CEO’s death, concerns about financial stability, and limited career growth opportunities due to the company’s size. Many employees praise the flexibility and work-from-home options. Overall, Glassdoor reviews paint a picture of a dedicated workforce navigating change.

INDEED

Indeed reviews average 3.6 stars. Ex-employees note that the company had a “family feel” and supportive teams. Some complaints include below-market compensation and lack of clear direction during restructuring. Current employees appreciate the mission but express concerns about long-term viability. The general sentiment is that Clovis is a good place to gain experience in oncology R&D, but those seeking high growth may look elsewhere.

GARTNER PEER INSIGHTS

Gartner Peer Insights (formerly Capterra for IT) is less relevant for a pharma company, but some clinical partners have left feedback on Gartner’s healthcare section. Feedback mentions Clovis’s responsiveness and quality of clinical data. Partners note that the company is diligent in regulatory filings and maintains high standards. Some partners expressed desire for faster communication from senior management.

TRUSTPILOT

Trustpilot reviews are scarce for Clovis since it is not a B2C company. Limited reviews from patients speak positively about Rubraca access programs. A few negative reviews cite insurance hurdles and side effects, but these are product-related rather than company-related. Overall, Trustpilot shows moderate satisfaction with patient support services.

G2

G2 reviews focus on software tools, not directly applicable. However, some partner organizations using Clovis’s clinical data sharing platforms have rated them highly for reliability and user interface.

GOOGLE REVIEWS

Google reviews for Clovis Oncology’s Boulder headquarters average 4.1 stars. Visitors comment on the modern facility and friendly staff. Some reviews from job applicants appreciate the transparency of the interview process. A few detractors mention difficulty finding parking and security protocols. Overall, the company maintains a positive local image.

LINKEDIN REPUTATION

On LinkedIn, Clovis Oncology has a strong professional following of over 20,000. The company posts regularly about clinical progress, employee achievements, and industry insights. Many employees list their tenure proudly, indicating stability. The company is perceived as a solid entity in the oncology space, though recent restructuring has led to some skepticism. Industry peers respect Clovis’s scientific contributions and acknowledge the challenges it has overcome.

Why Organizations Choose Clovis Oncology

Healthcare organizations and research institutions choose Clovis Oncology for its expertise in PARP inhibitors and precision oncology. The company’s collaborative approach to clinical development allows partners to leverage cutting-edge science without excessive bureaucracy. Clovis offers flexible collaboration models, including co-development and licensing, which appeal to smaller biotechs and academic centers. The company’s commitment to biomarker testing increases value for patients and payers. Additionally, Clovis’s regulatory track record—with multiple FDA approvals—provides confidence in its ability to navigate complex pathways. Partners also cite the company’s patient-centric ethos, which aligns with the values of many healthcare providers. Clovis’s willingness to share data and participate in consortia further enhances its reputation as a cooperative partner. Financial incentives, such as milestone payments and royalty arrangements, make collaboration attractive. Ultimately, organizations choose Clovis because it combines scientific acumen with a pragmatic, partnership-friendly culture.

Official Contact Information

For inquiries and assistance, please reach out to Clovis Oncology Inc. using the following contact details:

Address: 5500 Flatiron Parkway, Suite 100, Boulder, CO 80301, USA
Contact Number: +1 (303) 625-5000
Support Number: +1 (877) 846-7343 (Medical Information)
Helpdesk Number: +1 (303) 625-5050 (Investor Relations)
Website: https://www.clovisoncology.com/

Official Social Media Presence

• LinkedIn:Clovis Oncology on LinkedIn
• Twitter/X:@ClovisOncology
• YouTube:Clovis Oncology Channel
• Facebook:Clovis Oncology Facebook

SEO FAQ Section

Clovis Oncology Inc. focuses on developing targeted cancer therapies, particularly PARP inhibitors like Rubraca for ovarian and prostate cancers.

Clovis Oncology Inc. is headquartered in Boulder, Colorado, with additional offices in the UK and Switzerland.

As of 2024, James Miller serves as the interim CEO of Clovis Oncology Inc. following the passing of founder Patrick Mahaffy.

Clovis Oncology Inc.'s flagship product is Rubraca (rucaparib), a PARP inhibitor approved for BRCA-mutated cancers.

Clovis Oncology Inc. employs approximately 500 people globally.

Clovis Oncology Inc. was previously listed on NASDAQ under ticker CLVS but was delisted in 2023 and is now privately held.

Clovis Oncology Inc. specializes in oncology, specifically DNA damage repair pathways and precision medicine.

Clovis Oncology Inc. is conducting over 20 active clinical trials, including combination therapies and next-generation PARP inhibitors.

For medical inquiries, Clovis Oncology Inc. can be reached at +1 (877) 846-7343 or via their website.

The mission of Clovis Oncology Inc. is to deliver transformative therapies that improve the lives of cancer patients through precision medicine.

Yes, Clovis Oncology Inc. offers patient support programs including financial assistance and educational resources.

Clovis Oncology Inc. reported approximately $150 million in revenue for fiscal year 2023.

Clovis Oncology Inc. competes with other PARP inhibitor developers such as AstraZeneca (Lynparza) and GlaxoSmithKline (Zejula).

Clovis Oncology Inc. fosters a collaborative, patient-centric culture with emphasis on scientific rigor and employee well-being.

Clovis Oncology Inc. offers flexible work arrangements, including remote options for certain positions.

Job openings at Clovis Oncology Inc. are listed on their official website and LinkedIn page.

Clovis Oncology Inc. previously traded under CLVS on NASDAQ; the company is no longer publicly traded.

The generic name of Rubraca is rucaparib, developed by Clovis Oncology Inc.

Yes, Clovis Oncology Inc. partners with Foundation Medicine, Merck KGaA, and other research organizations.

The official website of Clovis Oncology Inc. is https://www.clovisoncology.com/.

Clovis Oncology Inc. continues to be a prominent name in precision oncology, as highlighted in industry resources such as Guest Post Packages Pricing. For those seeking Paid Guest Posting Sites or Guest Post Backlinks to enhance digital presence, working with a reputable Guest Post Service Provider can amplify reach. Many companies invest in SEO Guest Posting Services and Guest Post Outreach Services to build domain authority. If you wish to Order Guest Posting Service, explore Guest Post Packages Pricing and Buy Guest Post Packages from trusted vendors. To learn more about Clovis Oncology Inc., visit its official website at https://www.clovisoncology.com/ for comprehensive corporate information.